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Abstract
Background: Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen
presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We
sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to improve long term
outcomes.
Methods: Eligible patients were HD IL-2 eligible with metastatic BRAF V600 mutated melanoma. Cohort 1 was
treatment naïve and received vemurafenib 960 mg BID for 6 weeks before HD IL-2. Cohort 2 received vemurafenib
for 7–18 weeks before enrollment. Both cohorts received HD IL-2 at 600,000 IU/kg every 8 h days 1–5 and days 15–
19. The primary objective was to assess complete responses (CR) at 10 weeks ±3 (assessment 1) and 26 weeks ±3
(assessment 2) from the start of HD IL-2.
Results: Fifty-three patients were enrolled, (cohort 1, n = 38; cohort 2, n = 15). Of these, 39 underwent assessment 1
and 15 assessment 2. The CR rate at assessment 1 was 10% (95% CI 3–24) for both cohorts combined, and 27%
(95% CI 8–55) at assessment 2. Three-year survival was 30 and 27% for cohort 1 and cohort 2, respectively. No
unexpected toxicities occurred. A shift in the melanoma treatment landscape during this trial adversely affected
accrual, leading to early trial closure.
Conclusions: Vemurafenib in sequence with HD IL-2 did not change the known toxicity profile for either agent.
Lower than expected response rates to vemurafenib were observed. Overall response rates and durability of
responses appear similar to that observed with HD IL-2 alone.
Trial registration: NCTN, NCT01683188. Registered 11 September 2012, http://www.clinicaltrials.gov/NCT01683188
Keywords: High-dose interleukin-2, Vemurafenib, BRAF-mutated metastatic melanoma, Multicenter, Phase II
* Correspondence: jclark@lumc.edu
1Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 S.
First Avenue, Maywood, IL 60153, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Clark et al. Journal for ImmunoTherapy of Cancer  (2018) 6:76 
https://doi.org/10.1186/s40425-018-0387-x
Background
Treatment of metastatic malignant melanoma has dra-
matically advanced with the development of targeted
agents and immunotherapy in the recent past. Targeting
the MAPK pathway with BRAF inhibitors, MEK inhibi-
tors, or the combination, leads to high response rates
and progression free survivals of roughly 7 months for
single agents [1–3], to about 11 months for combination
regimens [4, 5]. Approved immunotherapies now include
high dose interleukin-2 (HD IL-2) and the immune
checkpoint inhibitors, (ipilimumab, nivolumab, pembro-
lizumab). Durable responses are consistently observed in
a small percentage of patients with metastatic melanoma
treated with HD IL-2 [6–8]. Higher response rates are
observed with immune checkpoint inhibitors [9–13],
especially with combination anti-CTLA and anti-PD1
agents [14–16], but longer follow up is required to deter-
mine the durability of these responses and more recent
studies report acquired resistance to these agents [17].
Preclinical studies suggest that oncogenic BRAF
(BRAF V600E) may contribute to immune escape in
melanoma [18], and that blocking its activity via MAPK
inhibition leads to increased expression of melanocytic
differentiation antigens (MDAs) [19, 20] with significantly
enhanced recognition by antigen-specific T lymphocytes
[20, 21], enhanced antigen presentation [22, 23], without
diminishing T-cell function [24], and change in the
tumor-produced immune environment [25]. The combin-
ation of BRAF inhibition with systemic immunotherapy is
therefore an appealing therapeutic approach in the treat-
ment of patients with advanced melanoma. That is, the ef-
fects of BRAF inhibition, including disease reduction and
control for several months may enhance the likelihood of
complete response to HD IL-2 therapy with subsequent
anticipated improved durability of these responses.
In this open-label phase 2 trial we sequenced the BRAF
inhibitor vemurafenib with HD IL-2 in the treatment of
patients with stage IV, metastatic BRAF-mutated malig-
nant melanoma and assessed the toxicity and efficacy
specifically with regard to the complete response rate
from this combination.
Methods
Patients
Eligible patients were age ≥ 18 years with histologically
confirmed, not surgically resectable due to extent of
disease, measurable stage IV BRAF V600E- or V600 K-mu-
tated malignant melanoma. Patients had to meet require-
ments for HD IL-2 therapy as previously described [6] and
vemurafenib therapy per institutional guidelines. Treat-
ment naïve patients were enrolled in Cohort 1; patients
who had been receiving active treatment with vemurafenib
for 7 to 18 weeks were enrolled in Cohort 2. Patients were
excluded if they had received prior treatment with HD
IL-2, ipilimumab or other highly selective BRAF, MEK,
NRAS, or cMET inhibitors. Prior treatment with an
anti-PD-1 or anti-PDL-1 antibody was allowed. Exclusion
also included a prolonged QTc interval of > 500 ms;
known or suspected infection with HIV, hepatitis C, hepa-
titis B or other infectious hepatitis; pregnant or nursing
women; untreated brain metastases; prior investigational
drug within 30 days. Human investigations were per-
formed after approval by an institutional review board or
ethics committee at each participating institution and in
accordance with an assurance filed with and approved by
the U.S. Department of Health and Human Services.
Written informed consent was obtained on all patients.
Study design and treatment
The study was approved by the institutional review
board or ethics committee at each participating institu-
tion. Eligible patients who were treatment naïve were
enrolled in Cohort 1 and received vemurafenib 960 mg
by mouth twice daily for 6 weeks prior to receiving
inpatient HD IL-2. Cohort 2 patients included eligible
patients who had been receiving vemurafenib therapy
for 7 to 18 weeks with stable or responding disease prior
to enrollment. Baseline imaging studies were performed
prior to starting vemurafenib in Cohort 1 and prior to
starting HD IL-2 in Cohort 2. Both cohorts received HD
IL-2 at 600,000 IU/kg intravenously over 15 min every
8 h for a maximum of 14 doses days 1–5, (cycle 1), and
days 15–19, (cycle 2). Each course consisted of 2 cycles.
Vemurafenib was held during inpatient HD IL-2 therapy,
(Fig. 1), and resumed during the 9 days between cycles
and at the completion of cycle 2. Dose adjustments of
vemurafenib or withholding of HD IL-2 doses were
performed by the respective treating physicians based on
accepted standards of care for each of these agents. QTc
intervals were reviewed daily for changes during each 5
day cycle of HD IL-2 dosing.
Study assessments/statistical analysis
Baseline imaging for cohort 1 occurred within 4 weeks
of starting vemurafenib whereas for cohort 2, baseline
imaging occurred after patients had been receiving
vemurafenib for > 7 weeks but < 18 weeks and either an
objective response or stable disease had to have been
observed before enrollment and initiation of HD IL-2
therapy. Disease response assessment occurred at week
10 ± 3 weeks, (assessment 1), and at week 26 ± 3 weeks,
(assessment 2), from the start of HD IL-2 dosing.
Patients received up to 2 courses of HD IL-2 if evidence
of disease response was observed after the first course.
Course 2 began at least 8 weeks after the completion of
course 1. RECIST and immune-related response criteria
(irRC) were used to assess response [26].
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Cohort 1 was used to define the study size and stat-
istical validity with the comparator being historical
controls using data from BRAF positive patients from
the Melanoma Select study (NCT01288963) [27]. The
initial design was to enroll 135 subjects in Cohort 1.
Based on a one-sample binomial test (using normal
approximation), a sample size of 135 would have 80%
power to detect a significant difference using a
one-sided test with α = 0.05% if the true complete re-
sponse (CR) rate for naïve subjects treated with
6 weeks of vemurafenib prior to adding HD IL-2 was
twice the CR rate of the historical control for HD
IL-2 (12% vs 6%). Up to 50 subjects were allowed to
be enrolled in Cohort 2. This cohort was designed to
evaluate whether additive or synergistic clinical benefit or
toxicity was observed in BRAF-mutated melanoma pa-
tients treated with vemurafenib as a single agent for > 7 to
18 weeks prior to the first course of HD IL-2 therapy in
conjunction with continued vemurafenib.
Secondary endpoints included (1) assessment of tumor
response in patients with CR or near CR (> 90%) after
discontinuation of vemurafenib, (2) compare progression
free survival (PFS) from initiation of vemurafenib
between Cohort 1 and Cohort 2 patients, (3) determine
the duration of response in patients treated with vemur-
afenib and HD IL-2, (4) compare overall PFS with the
historical data using vemurafenib or HD IL-2 alone, (5)
compare safety between Cohort 1 and Cohort 2 patients,
(6) compare safety between patients treated with vemur-
afenib and HD IL-2 versus historical HD IL-2 alone, (7)
explore potential biomarkers for their predictive value in
combination therapy of vemurafenib and HD IL-2, (8)
assess treatment response to retreatment with vemurafe-
nib in “CR” patients progressing on no therapy.
Results
A total of 53 patients with BRAF V600-mutated meta-
static melanoma were enrolled onto this trial. Cohort 1
included 38 patients and cohort 2, 15 patients, none of
whom received prior anti-PD1 or anti-PDL1 therapy
(Table 1). All evaluable patients received vemurafenib
and at least one dose of HD IL-2. Of the 53 patients
enrolled, 39 completed assessment 1 and 15 completed
assessment 2, respectively. A caveat to this trial required
that patients be enrolled into the PROCLAIM registry
[27] once they started HD IL-2 therapy, for purposes of
capturing survival data. Fourteen patients’ data were not
captured for assessment 1 for various reasons: seven
patients never proceeded on to HD IL-2 treatment, thus
they were not entered into the PROCLAIM registry, and
as such their response information was not captured. Of
these seven, two patients experienced an adverse event
on vemurafenib and the decision was made not to
proceed with HD IL-2 therapy; one patient withdrew
consent before receiving HD IL-2; two patients were un-
able to continue on protocol treatment due to insurance
issues; one patient experienced progression of disease
while taking vemurafenib thus did not proceed onto HD
IL-2 treatment; one patient chose not to proceed with
HD IL-2 treatment. Of the other seven patients who did
not undergo assessment 1: in two patients support for
the trial terminated prior to assessment 1 and they were
treated off study; four patients withdrew consent after
starting HD IL-2; one patient experienced early disease
progression shortly after starting HD IL-2 therapy.
No difference between RECIST and irRC was ob-
served. The best overall response rate, (ORR) (CR/PR),
at assessment 1 was 27% (95% CI 12–46) and disease
control rate, (CR/PR/SD) was 77% (95% CI 58–90) for
Fig. 1 Treatment Schema
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Table 1 Patient Demographics
Characteristic Cohort 1 Cohort 2
Vemurafenib 6 weeks (N = 38) Vemurafenib 7–18 weeks (N = 15)
Age (yr)
Mean (SD) 48.6 (12.79) 48.5 (13.90)
Median 50.5 48.0
Range 21–73 26–67
Gender – no. (%)
Male 15 (39.5) 6 (40.0)
Female 23 (60.5) 9 (60.0)
Race – no. (%)
White 35 (92.1) 15 (100.0)
Decline 2 (5.3) 0 (0.0)
Other 1 (2.6) 0 (0.0)
Metastasis stage – no. (%)
M1a 9 (23.7) 2 (13.3)
M1b 13 (34.2) 3 (20.0)
M1c 16 (42.1) 10 (66.7)
LDH level – no. (%)
≤ ULN 17 (44.7) 5 (33.3)
> ULN 17 (44.7) 8 (53.3)
Not measured 4 (10.5) 2 (13.3)
Prior therapy – no. (%)
Surgery 34 (89.5) 13 (86.7)
Radiation 7 (18.4) 8 (53.3)
Chemotherapy 4 (10.5) 1 (6.7)
Anti-PD1/PDL1 0 0
Mutation – no. (%)
BRAF 38 (100.0) 15 (100.0)
cKIT 1 (2.6) 0 (0.0)
Other 1 (2.6) 0 (0.0)
Performance Status
0 24 (63.2) 8 (53.3)
1 14 (36.8) 7 (46.7)
Race of ‘Other’ had the description ‘Not specified’ recorded
Table 2 Best Overall Response
Group Cohort 1 (N = 30) Cohort 2 (N = 15) Assessment 1 (N = 39) Assessment 2 (N = 15)
Complete Response 3 (10%) 1 (7%) 4 (10%) 4 (27%)
95% CI (%) (2, 27) (0.2, 32) (3, 24) (8, 55)
Response (CR/PR) 8 (27%) 4 (27%) 11 (28%) 9 (60%)
95% CI (%) (12, 46) (8, 55) (15, 45) (33, 84)
Disease Control (CR/PR/SD) 23 (77%) 11 (73%) 30 (77%) 15 (100%)
95% CI (%) (58, 90) (45, 92) (61, 89) (78, 100)
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cohort 1, (n = 30), and 27% (95% CI 8–55) and 73% (95%
CI 45–92) for cohort 2 (n = 15), respectively, (Table 2).
The CR rate was 10% (95% CI 2–17) for cohort 1 and
7% (95% CI 0.2–32) for cohort 2. At assessment 2, of the
15 patients who were assessed in both cohorts, the ORR
was 60% (95% CI 33–84) and the disease control rate
was 100% (95% CI 78–100). The median PFS was
5.3 months (95% CI 3.4–7.5) for cohort 1 and 8.3 months
(95% CI 4.0–35.3) for cohort 2, (p-value = 0.0874),
(Fig. 2). The duration of response ranged from 0.27 to
17+ months for all responders, and for those with stable
disease up to 18.1+ months (Table 3). The median OS
was 16.1 months (95% CI, 9.2–34.9) for cohort 1 and
14.9 months (95% CI 4.8–35.3) for cohort 2, (p-value =
0.9709), (Fig. 3). The 1, 2 and 3-year survivals were
similar in both cohorts, (Table 4). No subjects who
achieved a CR recurred.
No unexpected toxicities were observed with either
vemurafenib or with HD IL-2. One patient in each cohort
experienced a grade 3 rash with vemurafenib. Typical HD
IL2-related toxicities including constitutional symptoms
and capillary leak syndrome were observed in both
cohorts without excess cardiac, hepatic, pulmonary, renal
or skin toxicities beyond that expected with this agent. No
prolongation of QT interval was observed in patients
treated with HD IL-2 in either cohort. There were no
treatment related deaths.
Although our intent was to pursue predictive
biomarker data, due to funding issues and early closure
this endeavor was aborted. A shift in the melanoma
treatment landscape during this trial adversely affected
accrual, in that combination BRAF/MEK inhibitor
therapy soon became an approved and common
standard treatment approach, while durable responses
were achieved in a substantial percentage of patients
treated with checkpoint inhibitors, which led to early
trial closure.
Discussion
Treatment options for advanced malignant melanoma have
expanded significantly in the past number of years. When
this trial was first conceptualized, in early 2011, those op-
tions were limited. HD IL-2 was the first systemic immuno-
therapy approved for patients with advanced melanoma but
efficacy was observed in a select number of patients. Dra-
matic responses to the BRAF inhibitor, vemurafenib, and
preclinical as well as early clinical reports of enhanced anti-
gen expression and a favorable tumor microenvironment in
patients treated with such targeted agents led to our at-
tempt to combine this agent in BRAF-mutated melanoma
[19–25]. Combination BRAF-MEK inhibitor therapy in this
patient population was not yet approved when this trial
Fig. 2 Progression-Free Survival by Cohort
Table 3 Duration of Response (Days)
Response Cohort 1 Cohort 2
Complete Response Mean (SD) 84 (93.8) –
Median 56 –
Range 8–189 (ongoing)
Partial Response Mean (SD) 194 (180.0) 113 (103.0)
Median 118 133
Range 77–512 1–204
Stable Disease Mean (SD) 125 (156.8) 127 (186.3)
Median 56 63
Range 1–509 1–544
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initiated. Patient accrual to this study was negatively
affected shortly after opening due to rapidly expanding
treatment options for this group of patients, thus the trial
closed to accrual prior to meeting its target population of
135 patients in Cohort 1.
The safety results of this study show vemurafenib com-
bined with HD IL-2 did not change the known safety pro-
file of either drug. No dose reductions were required for
vemurafenib and there were no treatment related deaths.
The overall response rate of approximately 27% for each
cohort observed at assessment 1 was lower than expected
for unclear reasons. One would expect a response rate of
40–50% for vemurafenib alone [1, 2], whereas response
rates to HD IL-2 alone are consistently roughly 15–28% [6,
28, 29], although caution must be taken when comparing
the current results to previously published data. Assess-
ment 1 occurred at 10 ± 3 weeks from the start of HD IL-2.
In Cohort 1, vemurafenib was taken for 6 weeks prior to
starting HD IL-2, and in Cohort 2, vemurafenib was taken
for 7 to 18 weeks prior to starting HD IL-2 but patients
had to have had stable or responding disease before enroll-
ment. Vemurafenib was held during each five-day cycle of
inpatient HD IL-2 therapy in order to avoid excess toxicity
especially hepatic or cardiac in nature. Systemic HD IL-2
may have adversely enhanced immunosuppression, e.g. via
upregulating Treg function, which may help explain the
dampening effect of vemurafenib therapy and may serve as
one potential explanation for this lower than expected re-
sponse rate. It is conceivable that if combination
BRAF-MEK inhibitor therapy was used instead of single
agent vemurafenib that observed response rates would have
been higher. Biomarker assessment would enhance a better
understanding of such an effect, but these assessments were
not performed in this trial. Sullivan and colleagues have
made an initial attempt at these evaluations in a similar
smaller trial [30]. Disease control rate and 3-year overall
survival, however, were as would be expected with HD IL-2
therapy alone in patients with advanced malignant melan-
oma [8, 27–29]. Thus this combination does not appear to
induce and overall negative clinical outcome.
Combination targeted therapy with systemic immuno-
therapy is a valid approach worth investigation based on
preclinical models and early clinical results [18–25, 31].
Caution must be heeded however as unexpected untoward
toxicity may arise [32]. Active studies are ongoing using
other BRAF/MEK combinations and immune checkpoint
inhibitors, results of which are eagerly anticipated.
Conclusions
In conclusion, results of this trial reveal that the com-
bination of vemurafenib and HD IL-2 in the treatment
of BRAF-mutated metastatic malignant melanoma was
safe but without added clinical benefit beyond what
would be expected with either agent alone. Accrual to
the study was halted far short of planned due to a dra-
matic shift in the treatment landscape of this previously
poorly responsive disease. Future alternative combin-
ation approaches remain worthy investigative endeavors.
Fig. 3 Overall Survival by Cohort
Table 4 1-, 2-, 3-year Survival
Survival Cohort 1 (N = 30) Cohort 2 (N = 15)
1-year 18 (60%) 8 (53%)
2-year 14 (46.7%) 6 (40%)
3-year 9 (30%) 4 (26.7%)
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